Correlation Between Erasca and Apellis Pharmaceuticals
Can any of the company-specific risk be diversified away by investing in both Erasca and Apellis Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Erasca and Apellis Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Erasca Inc and Apellis Pharmaceuticals, you can compare the effects of market volatilities on Erasca and Apellis Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Erasca with a short position of Apellis Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Erasca and Apellis Pharmaceuticals.
Diversification Opportunities for Erasca and Apellis Pharmaceuticals
0.46 | Correlation Coefficient |
Very weak diversification
The 3 months correlation between Erasca and Apellis is 0.46. Overlapping area represents the amount of risk that can be diversified away by holding Erasca Inc and Apellis Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Apellis Pharmaceuticals and Erasca is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Erasca Inc are associated (or correlated) with Apellis Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Apellis Pharmaceuticals has no effect on the direction of Erasca i.e., Erasca and Apellis Pharmaceuticals go up and down completely randomly.
Pair Corralation between Erasca and Apellis Pharmaceuticals
Given the investment horizon of 90 days Erasca is expected to generate 2.88 times less return on investment than Apellis Pharmaceuticals. But when comparing it to its historical volatility, Erasca Inc is 1.06 times less risky than Apellis Pharmaceuticals. It trades about 0.08 of its potential returns per unit of risk. Apellis Pharmaceuticals is currently generating about 0.21 of returns per unit of risk over similar time horizon. If you would invest 2,734 in Apellis Pharmaceuticals on August 29, 2024 and sell it today you would earn a total of 529.00 from holding Apellis Pharmaceuticals or generate 19.35% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Weak |
| Accuracy | 100.0% |
| Values | Daily Returns |
Erasca Inc vs. Apellis Pharmaceuticals
Performance |
| Timeline |
| Erasca Inc |
| Apellis Pharmaceuticals |
Erasca and Apellis Pharmaceuticals Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Erasca and Apellis Pharmaceuticals
The main advantage of trading using opposite Erasca and Apellis Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Erasca position performs unexpectedly, Apellis Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Apellis Pharmaceuticals will offset losses from the drop in Apellis Pharmaceuticals' long position.| Erasca vs. Eliem Therapeutics | Erasca vs. Scpharmaceuticals | Erasca vs. Milestone Pharmaceuticals | Erasca vs. Seres Therapeutics |
| Apellis Pharmaceuticals vs. Eliem Therapeutics | Apellis Pharmaceuticals vs. Scpharmaceuticals | Apellis Pharmaceuticals vs. Milestone Pharmaceuticals | Apellis Pharmaceuticals vs. Seres Therapeutics |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Other Complementary Tools
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Stocks Directory Find actively traded stocks across global markets | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |